guest ::
| Home > Publications database > IMG-61. Assessment of18F-FET PET-based response to bevacizumab-based regimens in patients with glioblastoma at relapse using the PET RANO 1.0 criteria |
| Home > Publications database > IMG-61. Assessment of18F-FET PET-based response to bevacizumab-based regimens in patients with glioblastoma at relapse using the PET RANO 1.0 criteria |
| Abstract | FZJ-2026-01602 |
; ; ; ; ; ; ; ; ; ; ;
2025
This record in other databases:
Please use a persistent id in citations: doi:10.1093/neuonc/noaf201.1140
Abstract: AbstractBACKGROUNDWe evaluated the amino acid PET-based response assessment criteria (PET RANO 1.0) for their ability to predict longer overall survival (OS) in patients with glioblastoma treated with bevacizumab-based regimens at relapse.PATIENTS AND METHODSThirty-eight adult patients with IDH-wildtype glioblastoma were identified from three previously published studies. All patients (i) received bevacizumab in combination with a second agent (irinotecan, lomustine, or nivolumab), (ii) underwent MRI- and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET imaging at baseline and at a median time of 8 weeks (range, 4-12 weeks) after treatment initiation, and (iii) had available PET-derived parameters, i.e., metabolic tumor volume (MTV), maximum and mean tumor-to-brain ratios (TBRmax and TBRmean). A post-hoc analysis was performed to evaluate the predictive value of the PET RANO 1.0 criteria. In addition, ROC analyses were performed to define PET parameter thresholds for predicting an OS≥9 months. Furthermore, response prediction using the RANO 2.0 criteria for MRI was compared with the PET RANO 1.0 criteria.RESULTSAccording to the PET RANO 1.0 criteria, patients fulfilling the criterion Stable Disease (n=10), Partial Response (n=19), or Complete Response (n=1) had a significantly longer OS than patients with Progressive Disease (n=8) (9.0 vs. 4.0 months; P=0.001). Among the suggested thresholds by the PET RANO 1.0 criteria, only a MTV reduction ≥40% was significantly predictive of response (7.3 vs. 4.0 months; P=0.008). Optimal thresholds identified by ROC analysis differed from those proposed by the PET RANO 1.0 criteria. A reduction in MTV by ≥30% and in TBRmean by ≥4% were both predictive of longer OS (7.3 vs. 4.0 months; P=0.008, and 10.6 vs. 6.0 months; P=0.010, respectively). The RANO 2.0 criteria were less significant to predict a longer OS (9.0 vs. 6.0 months; P=0.015).CONCLUSIONPET RANO 1.0 criteria appear to be effective in predicting response to bevacizumab-based therapy in glioblastomas at relapse.
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; Nationallizenz
; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
